Latest Content

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

In patients with R/R multiple myeloma, real-world Elrexfio was associated with shorter time until progression but higher rates of response than Tecvayli.

Venclexta regimens showed comparable progression-free survival versus continuous Imbruvica.

For pediatric and young adult patients with B-cell acute lymphoblastic leukemia, removal of total body irradiation did not compromise efficacy.

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

CURE honored four individuals whose compassion and leadership shaped support education and empowerment for people living with blood cancers.

Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.

Dr. Amany Keruakous discussed how bispecific antibodies for multiple myeloma work by simultaneously targeting cancer cells and T cells.

Facing my cancer diagnosis, I learned it’s okay not to be okay and found comfort in laughter, honesty, and the support of loved ones.

Dr. Ajay Gupta of the Roswell Park Comprehensive Cancer Center discussed basics of gastrointestinal stromal tumors.